Trazodone: Nursing Drug Guide, Orthostasis, Priapism & NCLEX Review
Bedtime trazodone sedates through alpha-1 blockade and can drop blood pressure on standing—pair every evening dose with orthostatic checks, fall precautions, and priapism teaching in men, while screening for serotonergic overlap and antidepressant suicidality cues.
Orthostatic hypotension and syncope are reported with trazodone and worsen with antihypertensives, dehydration, and overlapping sedatives. In men, priapism (painful erection >6 hours; seek emergency care if >4 hours per labeling) can cause irreversible injury if delayed. Labeling carries a boxed warning for increased suicidal thoughts and behaviors in pediatric and young adult patients; trazodone is not approved in pediatric patients. Serotonin syndrome risk rises with MAO inhibitors (including linezolid), SSRIs, SNRIs, tramadol, and other serotonergic drugs. Wait at least 14 days between MAOI and trazodone therapy. Monitor for worsening depression, suicidality, and agitation at initiation and dose changes.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every bedtime dose, check orthostatic blood pressure, sedative overlap, and fall history—then teach men that any erection lasting more than four hours requires stopping trazodone and urgent medical evaluation.
Most common brand names
Trazodone is available generically and under brand names. Nurses often see low-dose bedtime orders for sleep even though FDA labeling is for major depressive disorder in adults—verify indication, dose, and tablet strength on every pass.
Common names include Desyrel (immediate-release tablets) and Oleptro (extended-release formulation where stocked). Trazodone is usually a single-entity tablet (50, 100, 150, or 300 mg strengths with score lines per labeling). It is frequently combined in practice with SSRIs, benzodiazepines, or antihypertensives rather than fixed-dose combination products.
Why we give it — Indications
FDA-approved labeling indicates trazodone for major depressive disorder (MDD) in adults. Many inpatient and community orders use lower bedtime doses for insomnia or agitated depression—those uses are prescriber-directed and not pediatric-approved.
| Use | Detail |
|---|---|
| Major depressive disorder (MDD) | Trazodone hydrochloride tablets are indicated for MDD in adults per DailyMed labeling. Antidepressant benefit may take weeks; sedation often appears earlier—do not confuse somnolence with mood improvement. |
| Off-label / common nursing contexts | Bedtime dosing for insomnia or agitation may appear on MARs though not listed as a labeled indication. Screen sedative burden and orthostatic risk whenever trazodone is ordered primarily for sleep. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Trazodone is a selective serotonin reuptake inhibitor and 5-HT2 receptor antagonist; the net antidepressant mechanism is not fully understood per labeling. It inhibits neuronal serotonin reuptake and antagonizes several monoaminergic receptors. Alpha-1 adrenergic antagonism is associated with postural hypotension—the bedside cue that distinguishes trazodone safety work from many other antidepressants.
Dosing overview
Dosing is titrated gradually. Drowsiness may require giving the largest portion at bedtime or reducing the dose per labeling. Always confirm strength, scored-tablet splitting instructions, and whether the patient ate a meal or snack before dosing.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; give the next dose at the scheduled time unless prescriber directs otherwise. If several doses are missed, abrupt restart may increase discontinuation symptoms—contact pharmacy before resuming after a prolonged gap.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (sedation) | Not specified as a single numeric value in the reviewed prescribing information | Drowsiness may appear before antidepressant benefit—do not use sedation alone as proof of effective MDD treatment |
| Peak plasma | ~1 hour fasting; ~2 hours with food | Labeling recommends taking shortly after a meal or snack; food increases amount absorbed and delays peak |
| Half-life | Not specified in the reviewed prescribing information nursing summary | Some patients accumulate drug in plasma per labeling—watch prolonged sedation when doses increase |
| Metabolism | CYP3A4 to active mCPP metabolite | Strong CYP3A4 inhibitors may require dose reduction; inducers may require increase—coordinate with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Titration
Start low and increase by 50 mg every 3–4 days based on response and tolerance. If drowsiness is excessive, give the major portion at bedtime or reduce dose per labeling—not upward titration beyond outpatient maximum (400 mg/day) without prescriber oversight.
Before you give it — Safety check
Pretreatment checks
- Orthostatic blood pressure and recent fall or syncope history—perform orthostatic blood pressure before first inpatient dose and after titration
- Complete medication reconciliation for MAOIs (including linezolid), SSRIs/SNRIs, tramadol, CNS depressants, QT-prolonging drugs, antihypertensives, and anticoagulants/antiplatelets
- Suicidality and bipolar screening at initiation; confirm tablet strength matches order; verify patient ate a meal or light snack (labeling recommends dosing shortly after food)
Contraindications
- Concomitant MAOIs or use within 14 days of stopping MAOIs—including linezolid or intravenous methylene blue—because of serotonin syndrome risk
- Known hypersensitivity to trazodone or formulation excipients (not further specified in the reviewed prescribing information)
- Do not initiate trazodone during active MAOI therapy; discontinue trazodone before starting MAOI treatment if clinically necessary per labeling
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Serotonergic drugs (SSRIs, SNRIs, tramadol, triptans, lithium, buspirone) | Increased serotonin syndrome risk; may occur even when trazodone is used alone but risk rises with overlap | Screen for agitation, hyperreflexia, autonomic instability, and confusion; hold trazodone and escalate if serotonin syndrome suspected |
| CNS depressants (alcohol, benzodiazepines, opioids) | Trazodone may enhance sedative effects; overdose deaths reported with concurrent CNS depressants per labeling | Avoid unplanned overlap with lorazepam or other sedatives; monitor level of consciousness and fall risk |
| Anticoagulants / antiplatelets / NSAIDs | Serotonin reuptake inhibition increases bleeding risk; warfarin may need INR monitoring when starting or stopping trazodone | Monitor for bruising or GI bleeding; trend INR with warfarin; avoid unplanned ibuprofen overlap without prescriber intent |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablets swallowed whole or broken in half along the score line; should not be chewed or crushed per labeling. Take shortly after a meal or light snack.
- Give the largest portion at bedtime when drowsiness requires it, per prescriber and labeling titration guidance
- Use correct score line when splitting tablets—labeling includes strength-specific splitting diagrams for 50–300 mg tablets
- Do not restart after missed doses without pharmacy guidance if multiple doses were skipped (discontinuation syndrome risk)
Labeling states tablets should be taken shortly after a meal or light snack. Food affects absorption (peak may delay to about 2 hours with food vs 1 hour fasting). Verify scored-tablet partial doses against pharmacy labeling—giving a whole 150 mg tablet for a 50 mg order is a common strength error.
Expected therapeutic response
- Gradual improvement in depressive symptoms over weeks—not immediate like a hypnotic
- Improved sleep latency when low-dose bedtime use is prescriber-intended, without excessive daytime sedation
- Stable orthostatic vital signs and absence of syncope, priapism, or serotonin syndrome signs
Red flags — Stop and act
Escalate urgently when orthostatic collapse, priapism, serotonin syndrome, arrhythmia, or suicidality emerges.
- Syncope, near-fall, or standing dizziness after trazodone—especially with antihypertensives or dose increases
- Painful or prolonged erection in men (>4 hours per labeling; priapism defined as >6 hours)—hold drug and seek emergency care
- Agitation, hyperreflexia, clonus, fever, or autonomic instability suggesting serotonin syndrome—especially after SSRI addition (e.g., sertraline)
- New suicidal ideation, worsening depression, mania, or behavioral activation—boxed warning population includes ages 18–24
- Palpitations, syncope with arrhythmia, or QT prolongation risk factors—obtain ECG and notify prescriber per protocol
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Drowsiness / sedation | Very common (41% outpatients vs 20% placebo in labeling trials) | Schedule largest dose at bedtime; fall precautions; hold if unable to arouse or unsafe orthostatics |
| Dizziness / light-headedness | Common (28% outpatients) | Orthostatic vitals; assist with ambulation; review antihypertensives and sedatives |
| Orthostatic hypotension / syncope | Reported; syncope 5% outpatients | Hold dose, notify prescriber, fall protocol; evaluate antihypertensive overlap |
| Dry mouth, blurred vision, constipation | Common anticholinergic-like effects | Oral care, vision safety, bowel protocol; differentiate from hyponatremia or serotonin syndrome |
| Priapism | Rare but serious postmarketing | Men: stop drug and emergency care if erection >4 hours; urology escalation |
| Serotonin syndrome | Serious; risk with serotonergic drugs and MAOIs | Hold trazodone and interacting agents; supportive care; toxicology per protocol |
| Suicidal thoughts/behaviors | Boxed warning ages 18–24 increased risk vs placebo | Monitor mood and behavior at initiation and dose changes; escalate emergent ideation |
| Hyponatremia / SIADH | Reported; sodium <110 mmol/L in cases | Check BMP if confusion or weakness; hold and treat per prescriber |
| QT prolongation / arrhythmia | Postmarketing including torsade de pointes at ≤100 mg | Hold and obtain ECG; review QT-prolonging co-medications |
| Increased bleeding | With antiplatelets/anticoagulants/NSAIDs | Monitor bruising, GI bleeding, INR with warfarin |
On a small screen, swipe or scroll sideways to see the full table.
Trial frequencies from DailyMed labeling Table 2 (inpatient/outpatient controlled studies). Postmarketing events may occur at rates not captured in trials.
Overdose, toxicity, and antidote
Death from overdose has occurred when trazodone was ingested with other CNS depressants (alcohol, benzodiazepines, barbiturates) per labeling. The most severe reactions with trazodone alone reported include priapism, respiratory arrest, seizures, and ECG changes including QT prolongation. Most frequent reactions include drowsiness and vomiting.
Antidote
There is no specific antidote for trazodone overdose in the reviewed prescribing information. Management is supportive—consider multiple drug involvement, monitor airway and cardiac rhythm, and contact local poison control or toxicology services per facility protocol.
For suspected overdose, initiate supportive care immediately and follow institutional toxicology protocols. Do not assume sedation alone means a benign course—priapism, seizures, and arrhythmias are reported.
Look-alike / sound-alike and error prevention
- Trazodone vs tramadol—both sedating serotonergic drugs with different roles; verify name and indication on MAR
- Trazodone vs trazodone ER (Oleptro)—do not substitute extended-release for immediate-release without prescriber order
- Strength errors—150 mg and 300 mg tablets have complex trisect scores; pharmacy should label split doses clearly
- Duplicate sedatives—bedtime trazodone plus PRN benzodiazepine or Z-drug without documented intent
- “Sleep dose” shorthand—50 mg vs 100 mg HS orders look similar; independent double-check at dispensing and bedside
- Sertraline + trazodone—common depression regimen but requires serotonin syndrome monitoring when either is new
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | May split along score line; do not chew or crush per labeling—verify enteral tube policy with pharmacy if crushing requested |
| Food timing | Give shortly after meal or light snack to match absorption labeling |
| Bedtime clustering | Trazodone, tamsulosin, and lorazepam at HS multiply orthostatic fall risk—stagger or hold per prescriber when syncope occurs |
| Commonly missed | Orthostatics after dose increase; priapism teaching in men; MAOI/linezolid history on admission |
| Ask pharmacy when | SSRI added to trazodone, CYP3A4 inhibitor started, scored-tablet dose unclear, or overdose suspected |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults and fall-risk patients | Use caution in geriatric patients; hyponatremia and orthostatic hypotension can cause unsteadiness and falls. Apply fall risk assessment when initiating or titrating. |
| Cardiac disease / QT prolongation risk | Avoid in known QT prolongation or with other QT-prolonging drugs; arrhythmias including torsade de pointes reported at doses ≤100 mg per labeling. Not recommended during initial recovery phase of myocardial infarction. |
| Men at priapism risk / bleeding risk | Use caution in sickle cell disease, leukemia, multiple myeloma, or penile anatomical deformity per labeling. Monitor bleeding when combined with antiplatelets, NSAIDs, or anticoagulants. |
| Pregnancy | Published human data have not identified a clear increased risk of major birth defects or miscarriage with trazodone, but studies cannot definitively rule out risk. Animal data showed fetal resorption at high doses. A pregnancy exposure registry exists for antidepressants—healthcare providers may register patients per labeling. Weigh untreated depression relapse risk against medication exposure with the prescriber. |
| Lactation | LactMed (April 2022) reports trazodone transfers into milk at low levels; relative infant dose is generally low and adverse infant effects have not been identified in limited reports, especially with maternal doses ≤100 mg at bedtime. Consider maternal clinical need, infant age, and monitoring. Data on milk production effects are limited. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Orthostatic vital signs, sedation level, and fall events after bedtime doses
- Mood, sleep, suicidality, and behavioral changes—especially first months and at dose changes per boxed warning
- Sodium on BMP if confusion or weakness suggests hyponatremia; INR if on warfarin; ECG if QT risk
Document
- Dose, strength, time, food intake, orthostatic findings, and sedative co-medications given
- Suicidality screening results at initiation/titration and patient/caregiver teaching on mood changes
- Priapism teaching documented for male patients; hold events and prescriber/pharmacy notification
Patient teaching
- Rise slowly from bed or chair; sit before standing; use call light for bathroom trips after bedtime dose
- Do not drive or operate machinery until you know how trazodone affects you—sedation can impair judgment per labeling
- Men: stop trazodone and seek emergency care for any erection lasting more than four hours, painful or not
- Report worsening depression, suicidal thoughts, agitation, insomnia, or unusual behavior immediately—especially in the first months of therapy
- Do not stop abruptly; discuss taper with prescriber to avoid discontinuation symptoms (dizziness, anxiety, electric-shock sensations)
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- MAOI or linezolid within 14 days, or active serotonergic overlap without pharmacy-approved plan
- Syncope, orthostatic BP drop with symptoms, or unwitnessed fall after recent trazodone dose until prescriber reviews
- Suspected priapism, serotonin syndrome, or new suicidal plan/intentional overdose
- Dispensed tablet strength does not match order (e.g., 150 mg tablet for 50 mg order)
- Patient unable to arouse, new arrhythmia symptoms, or symptomatic hyponatremia pending prescriber review
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Trazodone is often treated as a gentle sleep aid, but alpha-1 blockade and sedation cause real falls—especially when antihypertensives or benzodiazepines share the MAR. Build orthostatic checks and priapism teaching into every bedtime pass.
1. Check-before-you-give protocol
- Right patient, drug, strength, route, time—and confirm meal/snack within appropriate window
- Orthostatics and fall precautions current; no syncope since last dose
- Serotonergic and CNS depressant overlap reviewed with pharmacy when new orders appear
- Suicidality screen up to date when initiating or changing dose; male patients taught priapism red flags
2. High-alert and safety badge
Sedating antidepressant — orthostasis, falls, priapism, serotonin syndromeNot on every institutional high-alert list, but trazodone combines antidepressant suicidality monitoring with orthostatic hypotension, priapism, and serotonergic interaction risk—use the same independent double-check rigor as other sedating psychotropics.
3. Clinical workflow: hold and question rules
- If standing BP drops ≥20 mmHg systolic or ≥10 mmHg diastolic with symptoms, hold the dose and notify prescriber before giving more
- If an SSRI was added to bedtime trazodone without a documented switch plan, hold and call pharmacy before either drug is given
- Any male patient reporting prolonged erection triggers immediate hold and emergency pathway—do not wait for morning rounds
4. Critical teach-back questions
- “What will you do if you feel dizzy when you stand up after taking trazodone?” (Patient should say sit or lie down, rise slowly, use assistance, and notify the nurse or prescriber if dizziness persists.)
- “If you are a man, when must you stop trazodone and seek emergency care?” (Patient should say any erection lasting more than four hours, whether painful or not, requires stopping the drug and urgent medical attention.)
5. Care coordination
Pharmacist: MAOI washout, SSRI/SNRI switches, CYP3A4 interaction review, scored-tablet verification, and overdose supportive-care guidance
Psychiatry / prescriber: Suicidality escalation, mania activation, priapism/urology referral, and taper plans when stopping therapy
🧠 Quick mental checklist
- Does the tablet strength match the order after splitting?
- Any new SSRI, SNRI, tramadol, linezolid, or sedative on the MAR?
- Orthostatics and fall events since the last bedtime dose?
- Suicidal ideation or behavioral change since initiation or titration?
- For men: priapism teaching done; for all: meal/snack before dose?
Trazodone NCLEX practice questions
Practice NCLEX-style clinical judgment practice for trazodone using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), post-hold trend interpretation, matrix urgency for orthostasis versus priapism, priapism teaching MCQ, and MAOI washout cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Trazodone 100 mg PO at bedtime — increased from 50 mg three days ago for insomnia and depression
- Lisinopril 10 mg PO each morning
- Tamsulosin 0.4 mg PO at bedtime
- Lorazepam 0.5 mg PO HS PRN anxiety — given last night
- Sertraline 25 mg PO each morning — started yesterday per psychiatry
- Today BMP: sodium 131 mmol/L (134 two days ago), potassium 4.0, creatinine 1.0 mg/dL
- CBC unchanged; no baseline QTc documented in chart
- Admission sodium 136 mmol/L
- Lying: BP 128/72, HR 76
- Standing (1 min): BP 92/58, HR 102 — patient reports room spinning
- Last fall: found on bathroom floor at 0545 today, no head strike reported
- SpO2 97% on room air; temp 36.8 °C
- 2200: Trazodone 100 mg given after snack; asleep within 30 min
- 0545: Found sitting on floor after attempting to stand from toilet—no LOC recalled
- 0700: Alert but groggy; denies chest pain; asks to go back to bed
- Fall risk score increased; bed alarm activated; patient prefers independent bathroom trips
Answer key & rationale
Frequently asked questions
Why must nurses check orthostatic blood pressure before giving trazodone?
Trazodone antagonizes alpha-1 adrenergic receptors, causing hypotension including orthostatic hypotension and syncope per prescribing information. Risk increases with antihypertensives such as tamsulosin or lisinopril and with dose titration. Check lying and standing blood pressure and heart rate, apply fall precautions, and hold the dose if symptomatic orthostasis occurs until the prescriber reviews.
When should a nurse hold trazodone because of priapism concern?
Hold trazodone and seek emergency medical attention if a man has an erection lasting greater than four hours, whether painful or not, per labeling. Priapism greater than six hours has been reported and can cause irreversible erectile tissue damage if treatment is delayed. This is a urologic emergency—not a wait-until-morning finding.
How long must a nurse wait after stopping an MAOI before starting trazodone?
At least 14 days must elapse after discontinuing an MAOI antidepressant before initiating trazodone, and at least 14 days after stopping trazodone before starting an MAOI. The same separation applies to linezolid and intravenous methylene blue unless pharmacy and the prescriber direct otherwise per labeling.
What sedating drugs should not overlap with trazodone without a plan?
Labeling warns that trazodone may enhance effects of alcohol, barbiturates, and other CNS depressants. Overdose deaths have occurred with concurrent alcohol, benzodiazepines, and other sedatives. Review benzodiazepines, opioids, and other sedating psychotropics on the MAR before bedtime trazodone and monitor for excessive sedation and falls.
Is trazodone safe during breastfeeding?
LactMed reports trazodone passes into breast milk at low levels with relative infant doses generally low; adverse infant effects have not been identified in limited reports, especially with maternal bedtime doses of 100 mg or less. Weigh benefits of breastfeeding against maternal need and potential infant exposure with the prescriber.
References
-
U.S. National Library of Medicine. Trazodone hydrochloride tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704aebf9-2fff-4ef3-8323-9ff0d7f0ffd9
-
U.S. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidality-children-and-adolescents-being-treated-antidepressant
-
U.S. National Library of Medicine. Trazodone hydrochloride — Medication Guide. DailyMed.https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=704aebf9-2fff-4ef3-8323-9ff0d7f0ffd9
-
Drugs and Lactation Database (LactMed). Trazodone. Bethesda (MD): National Institute of Child Health and Human Development; updated April 18, 2022.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM316/
-
U.S. National Library of Medicine. Trazodone — MedlinePlus consumer summary.https://medlineplus.gov/druginfo/meds/a681038.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.